8-K: UroGen Pharma Announces Positive Phase 3 Data and 2024 Financial Results

UroGen Pharma reports positive 18-month duration of response data from the Phase 3 ENVISION trial for UGN-102 and announces its fourth quarter and full year 2024 financial results, including JELMYTO revenue growth.

Summary

• UroGen Pharma announced its financial results for the fourth quarter and full year ended December 31, 2024.
• The company reported an 18-month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION trial of UGN-102.
• The New Drug Application (NDA) for UGN-102 is under review by the FDA with a PDUFA target action date of June 13, 2025.
• UroGen acquired ICVB-1042, a next-generation investigational oncolytic virus.
• JELMYTO achieved net product revenue of $90.4 million in 2024, a 12% increase driven by underlying demand.
• The company had $241.7 million in cash, cash equivalents, and marketable securities as of December 31, 2024.
• UroGen expects full-year 2025 net product revenues from JELMYTO to be in the range of $94 to $98 million.
• Full-year 2025 operating expenses are expected to be in the range of $215 to $225 million.

Sentiment

Score: 7

Explanation: The announcement is generally positive due to the promising clinical data for UGN-102 and the continued growth of JELMYTO, but the net loss and increasing operating expenses temper the overall sentiment.

Positives

• The 18-month DOR data for UGN-102 from the ENVISION trial is positive, showing a high duration of response.
• The FDA's review of the UGN-102 NDA with a PDUFA date set provides a clear timeline for potential approval.
• JELMYTO's revenue growth indicates strong demand and market acceptance.
• The acquisition of ICVB-1042 expands UroGen's pipeline and potential for future growth.
• UroGen's cash position of $241.7 million provides financial stability and resources for ongoing development and commercialization efforts.
• The long-term study on JELMYTO showed a 68% recurrence-free survival rate at three years across a broad patient population with LG-UTUC.

Negatives

• UroGen reported a net loss of $126.9 million for the full year 2024.
• Operating expenses are expected to be between $215 and $225 million for 2025.
• CREATES Act sales decreased to $3.0 million in 2024 compared to $4.4 million in 2023.

Risks

• The FDA may delay or reject the UGN-102 NDA.
• Clinical trials may face unforeseen delays or complications.
• Competition in the urothelial cancer market could impact UroGen's commercial success.
• UroGen's financial condition may require additional capital in the future.
• The RTGel technology may not perform as expected.

Future Outlook

UroGen expects full-year 2025 net product revenues from JELMYTO to be in the range of $94 to $98 million and full-year 2025 operating expenses are expected to be in the range of $215 to $225 million.

Management Comments

• 2024 was a pivotal year for UroGen with achievements across our commercial business and pipeline, said Liz Barrett, President and Chief Executive Officer of UroGen.
• The progress with UGN-102 for low-grade intermediate-risk non-muscle invasive bladder cancer, including completion of the submission of our NDA ahead of schedule and compelling DOR data from the Phase 3 ENVISION trial, further positions us to launch a product that we believe will represent a paradigm shift in care, if approved.
• If approved, UGN-102 will address an estimated market opportunity of over $5 billion.

Industry Context

UroGen is focused on developing innovative solutions for urothelial and specialty cancers, addressing a significant unmet need in the treatment of bladder cancer and upper tract urothelial cancer, where current treatments have limitations and high recurrence rates.

Comparison to Industry Standards

• JELMYTO's performance can be compared to other intravesical therapies for urothelial cancer, such as Bacillus Calmette-Guérin (BCG), in terms of efficacy and safety.
• The 18-month DOR of 80.6% for UGN-102 is a key metric to compare against existing treatments and other investigational drugs in development for LG-IR-NMIBC.
• The $5 billion market opportunity for UGN-102, if approved, positions it as a potential blockbuster drug in the urothelial cancer space, comparable to other major oncology drugs.
• UroGen's acquisition of ICVB-1042 aligns with the industry trend of exploring oncolytic viruses as a novel approach to cancer treatment, similar to companies like Amgen with its oncolytic virus Imlygic.

Stakeholder Impact

• Positive clinical data and potential approval of UGN-102 could improve treatment options for patients with LG-IR-NMIBC.
• Continued growth of JELMYTO provides a valuable treatment option for patients with LG-UTUC.
• The company's financial performance and pipeline development impact shareholder value.
• Operating expense guidance impacts creditors and suppliers.

Next Steps

• UroGen awaits the FDA's decision on the UGN-102 NDA, with a PDUFA target action date of June 13, 2025.
• UroGen plans to initiate a Phase 3 trial to explore the safety and efficacy of UGN-104 in the first half of 2025.
• The company will continue to advance its early-stage pipeline, including the development of ICVB-1042.

Key Dates